重症COVID-19患者神经系统表现:前瞻性多中心登记研究PANDEMIC结果
PANDEMIC为前瞻性、多中心、观察性登记研究,纳入2020年4月至2021年9月德国19个ICU收治的392例有神经系统表现的COVID-19患者。研究期间15个参与中心共收治2681例COVID-19患者,新发神经系统疾病350例,提示COVID-19相关神经系统疾病在COVID-19 ICU患者中患病率为12.7%。最常见类别为脑病(46.2%;181/392)、脑血管病(41.0%;161/392)和神经肌肉疾病(20.4%;80/392)。院内死亡率36.0%(140/389),出院时存活者功能预后不良(mRS 3至5)占70.9%(161/227);脑出血(OR 6.2,95%CI 2.5-14.9,P<0.001)和急性缺血性卒中(OR 3.9,95%CI 1.9-8.2,P<0.001)是预后不良最强预测因素。35例脑脊液SARS-COV-2逆转录PCR检测仅3例阳性。
要点
- 在15个参与中心2681例COVID-19 ICU患者中,新发神经系统疾病350例,COVID-19相关神经系统疾病患病率为12.7%。
- 392例纳入分析患者中,脑病占46.2%(181/392)、脑血管病占41.0%(161/392)、神经肌肉疾病占20.4%(80/392)。
- 院内死亡率为36.0%(140/389);出院时存活者功能预后不良(mRS 3至5)占70.9%(161/227)。
- 脑出血(OR 6.2,95%CI 2.5-14.9,P<0.001)和急性缺血性卒中(OR 3.9,95%CI 1.9-8.2,P<0.001)是预后不良最强预测因素。
- 35例脑脊液SARS-COV-2逆转录PCR检测中仅3例阳性,未发现COVID-19直接侵犯神经系统的可靠证据。
适用人群与场景
- 2020年4月至2021年9月德国19个ICU收治的COVID-19合并神经系统表现患者,共392例纳入分析;70.7%(277/392)为男性,平均年龄65.3岁(SD ± 3.1)。
- 研究期间15个参与中心ICU共收治2681例COVID-19患者,新发神经系统疾病350例由这些中心报告。
红旗征与不能漏的情况
- 脑出血(OR 6.2,95%CI 2.5-14.9,P<0.001)是预后不良最强预测因素之一。
- 急性缺血性卒中(OR 3.9,95%CI 1.9-8.2,P<0.001)是预后不良最强预测因素之一。
研究设计与关键结果
- 研究类型:前瞻性、多中心、观察性登记研究PANDEMIC(Pooled Analysis of Neurologic DisordErs Manifesting in Intensive care of COVID-19),19个德国ICU参与,纳入392例。
- 主要结果:COVID-19相关神经系统疾病在COVID-19 ICU患者中患病率为12.7%(350/2681);脑病46.2%(181/392)、脑血管病41.0%(161/392)、神经肌肉疾病20.4%(80/392)。
- 脑脊液检查:35例脑脊液SARS-COV-2逆转录PCR检测仅3例阳性。
- 结局:院内死亡率36.0%(140/389);出院时存活者功能预后不良(mRS 3至5)占70.9%(161/227)。
- 预后预测:脑出血(OR 6.2,95%CI 2.5-14.9,P<0.001)和急性缺血性卒中(OR 3.9,95%CI 1.9-8.2,P<0.001)是预后不良最强预测因素。
证据类型、等级与局限
- 证据类型:前瞻性、多中心、观察性登记研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,由于未发现COVID-19直接侵犯神经系统的可靠证据,这些神经系统表现可能大部分是感染或严重危重病的间接副感染或感染后后遗症。
- 作者建议,应主动搜寻并治疗ICU神经系统并发症。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Neurologic manifestations are increasingly reported in patients with coronavirus disease 2019 (COVID-19). Yet, data on prevalence, predictors and relevance for outcome of neurological manifestations in patients requiring intensive care are scarce. We aimed to characterize prevalence, risk factors and impact on outcome of neurologic manifestations in critically ill COVID-19 patients.
METHODS: In the prospective, multicenter, observational registry study PANDEMIC (Pooled Analysis of Neurologic DisordErs Manifesting in Intensive care of COVID-19), we enrolled COVID-19 patients with neurologic manifestations admitted to 19 German intensive care units (ICU) between April 2020 and September 2021. We performed descriptive and explorative statistical analyses. Multivariable models were used to investigate factors associated with disorder categories and their underlying diagnoses as well as to identify predictors of outcome.
RESULTS: Of the 392 patients included in the analysis, 70.7% (277/392) were male and the mean age was 65.3 (SD ± 3.1) years. During the study period, a total of 2681 patients with COVID-19 were treated at the ICUs of 15 participating centers. New neurologic disorders were identified in 350 patients, reported by these centers, suggesting a prevalence of COVID-19-associated neurologic disorders of 12.7% among COVID-19 ICU patients. Encephalopathy (46.2%; 181/392), cerebrovascular (41.0%; 161/392) and neuromuscular disorders (20.4%; 80/392) were the most frequent categories identified. Out of 35 cerebrospinal fluid analyses with reverse transcriptase PCR for SARS-COV-2, only 3 were positive. In-hospital mortality was 36.0% (140/389), and functional outcome (mRS 3 to 5) of surviving patients was poor at hospital discharge in 70.9% (161/227). Intracerebral hemorrhage (OR 6.2, 95% CI 2.5-14.9, p < 0.001) and acute ischemic stroke (OR 3.9, 95% CI 1.9-8.2, p < 0.001) were the strongest predictors of poor outcome among the included patients.
CONCLUSIONS: Based on this well-characterized COVID-19 ICU cohort, that comprised 12.7% of all severe ill COVID-19 patients, neurologic manifestations increase mortality and morbidity. Since no reliable evidence of direct viral affection of the nervous system by COVID-19 could be found, these neurologic manifestations may for a great part be indirect para- or postinfectious sequelae of the infection or severe critical illness. Neurologic ICU complications should be actively searched for and treated.
参考来源
- Dimitriadis K, Meis J, Neugebauer H, et al. Neurologic manifestations of COVID-19 in critically ill patients: results of the prospective multicenter registry PANDEMIC. Crit Care. 2022. PMID: 35842675. doi:10.1186/s13054-022-04080-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。